A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT ID: NCT00404742


Title
A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
Purpose
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
Details
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Keywords
uveitis, calcineurin
Source
Lux Biosciences, Inc.
Sponsors
Lux Biosciences, Inc.
Status
Completed
Acronym
LUMINATE
Last Updated
20 Jun 2012
URL
Official Link
Locations
Austria, Canada, France, Germany, India, United Kingdom, United States